With earnings season winding down, regulatory and pipeline updates from the biotech sector are back in focus. Clovis Oncology’s CLVS shares plunged 70% as the company is possibly facing a delay in gaining FDA approval for its lead pipeline candidate. Meanwhile, companies like Gilead GILD and AbbVie ABBV provided pipeline and regulatory updates. Recap of the Week’s Most Important Stories 1. Clovis, which is focused on bringing cancer treatments to market, suffered a huge setback with the FDA asking the company to submit additional data on its lead pipeline candidate, rociletinib. Clovis is seeking both FDA and EMA approval for rociletinib for a...
↧